UNIGE document Scientific Article
previous document  unige:84018  next document
add to browser collection

Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

Moyers, Julie S
Charron, Maureen J
Vuguin, Patricia M
Powers, Alvin C
Published in eLife. 2016, vol. 5
Abstract Glucagon secretion dysregulation in diabetes fosters hyperglycemia. Recent studies report that mice lacking glucagon receptor (Gcgr(-/-)) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-producing β-cells. Here, we show that diabetes prevention in STZ-treated Gcgr(-/-) animals requires remnant insulin action originating from spared residual β-cells: these mice indeed became hyperglycemic after insulin receptor blockade. Accordingly, Gcgr(-/-) mice developed hyperglycemia after induction of a more complete, diphtheria toxin (DT)-induced β-cell loss, a situation of near-absolute insulin deficiency similar to type 1 diabetes. In addition, glucagon deficiency did not impair the natural capacity of α-cells to reprogram into insulin production after extreme β-cell loss. α-to-β-cell conversion was improved in Gcgr(-/-) mice as a consequence of α-cell hyperplasia. Collectively, these results indicate that glucagon antagonism could i) be a useful adjuvant therapy in diabetes only when residual insulin action persists, and ii) help devising future β-cell regeneration therapies relying upon α-cell reprogramming.
PMID: 27092792
Full text
Article (Published version) (2.4 MB) - public document Free access
Research group Types cellulaires pancréatiques pendant l'ontogénèse (522)
(ISO format)
DAMOND, Nicolas et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist. In: eLife, 2016, vol. 5. https://archive-ouverte.unige.ch/unige:84018

86 hits



Deposited on : 2016-05-31

Export document
Format :
Citation style :